2019 has been a landmark year and we expect momentum to accelerate as Hutchison China MediTech (HCM) continues on its path to become a global biotech with a marketed portfolio of innovation-led oncology drugs. Achievements in 2019 include the addition of Elunate on China’s exclusive NRDL list and surufatinib’s China NDA submission following impressive data in NET. 2020–21 are pivotal years. Surufatinib should become the second asset to launch in China, partner AZN could launch savolitinib in Chi ....
30 Jan 2020
2020 insights into a breakout year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2020 insights into a breakout year
HUTCHMED (China) Limited (HCM:LON) | 264 5.3 0.8% | Mkt Cap: 2,296m
- Published:
30 Jan 2020 -
Author:
Susie Jana -
Pages:
8
2019 has been a landmark year and we expect momentum to accelerate as Hutchison China MediTech (HCM) continues on its path to become a global biotech with a marketed portfolio of innovation-led oncology drugs. Achievements in 2019 include the addition of Elunate on China’s exclusive NRDL list and surufatinib’s China NDA submission following impressive data in NET. 2020–21 are pivotal years. Surufatinib should become the second asset to launch in China, partner AZN could launch savolitinib in Chi ....